Andrew Lovley1, Kimberly Raymond2, Spencer D Guthrie3, Michael Pollock4, Vaishali Sanchorawala5, Michelle K White2. 1. QualityMetric Incorporated, LLC, 1301 Atwood Avenue, Suite 216E, Johnston, RI, 02919, USA. alovley@qualitymetric.com. 2. QualityMetric Incorporated, LLC, 1301 Atwood Avenue, Suite 216E, Johnston, RI, 02919, USA. 3. Aurora Bio, San Francisco, CA, USA. 4. Akcea Therapeutics, Boston, MA, USA. 5. Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Abstract
BACKGROUND: Hereditary transthyretin (hATTR) amyloidosis is a rare, systemic, progressive, and life-threatening disease in which transthyretin proteins misfold and aggregate as insoluble amyloid deposits, disrupting nervous, cardiac, gastrointestinal, and other organ tissues. There are limited available data about the experience of patients living with hATTR amyloidosis. This study used a qualitative, non-interventional design to explore the humanistic burden of hATTR amyloidosis from the patient's perspective. RESULTS: Fourteen adults with hATTR amyloidosis, recruited from a patient advocacy group or an academic clinical center, participated in individual semi-structured interviews either in person or by telephone. Patients were asked to describe their experiences living with the condition, including symptoms and disease-related impacts on functioning and well-being, work, and activities of daily living (ADLs). Interviews were transcribed verbatim and analyzed for key concepts using a grounded theory approach. Patients described many symptoms of hATTR amyloidosis, particularly those associated with peripheral neuropathy such as pain, numbness, weakness, and paresthesia. Symptoms of autonomic neuropathy, such as gastrointestinal dysfunction, and symptoms related to cardiac dysfunction were also common. Worsening symptoms, especially those impacting patients' ability to walk or use their hands, often led to a loss of autonomy and an inability to work or perform ADLs. Disease-related disability also interfered with patients' participation in social activities, and contributed to feelings of fear, frustration, or sadness. CONCLUSIONS: The impacts of hATTR amyloidosis were profound for the patients interviewed for this study. They described a sense of loss as their condition progressed and impacted them physically, emotionally, and socially. Patients' reports of symptoms and impacts of hATTR amyloidosis illustrate the complex and varied manifestations of this disease. The progression of symptoms and increasing impacts of hATTR amyloidosis also highlight the need for an earlier diagnosis and effective clinical intervention to preserve patients' functioning and well-being.
BACKGROUND: Hereditary transthyretin (hATTR) amyloidosis is a rare, systemic, progressive, and life-threatening disease in which transthyretin proteins misfold and aggregate as insoluble amyloid deposits, disrupting nervous, cardiac, gastrointestinal, and other organ tissues. There are limited available data about the experience of patients living with hATTR amyloidosis. This study used a qualitative, non-interventional design to explore the humanistic burden of hATTR amyloidosis from the patient's perspective. RESULTS: Fourteen adults with hATTR amyloidosis, recruited from a patient advocacy group or an academic clinical center, participated in individual semi-structured interviews either in person or by telephone. Patients were asked to describe their experiences living with the condition, including symptoms and disease-related impacts on functioning and well-being, work, and activities of daily living (ADLs). Interviews were transcribed verbatim and analyzed for key concepts using a grounded theory approach. Patients described many symptoms of hATTR amyloidosis, particularly those associated with peripheral neuropathy such as pain, numbness, weakness, and paresthesia. Symptoms of autonomic neuropathy, such as gastrointestinal dysfunction, and symptoms related to cardiac dysfunction were also common. Worsening symptoms, especially those impacting patients' ability to walk or use their hands, often led to a loss of autonomy and an inability to work or perform ADLs. Disease-related disability also interfered with patients' participation in social activities, and contributed to feelings of fear, frustration, or sadness. CONCLUSIONS: The impacts of hATTR amyloidosis were profound for the patients interviewed for this study. They described a sense of loss as their condition progressed and impacted them physically, emotionally, and socially. Patients' reports of symptoms and impacts of hATTR amyloidosis illustrate the complex and varied manifestations of this disease. The progression of symptoms and increasing impacts of hATTR amyloidosis also highlight the need for an earlier diagnosis and effective clinical intervention to preserve patients' functioning and well-being.
Entities:
Keywords:
Amyloidosis; Burden of disease; Patient interviews; Qualitative; Quality of life; Rare disease
Authors: Thirusha Lane; Marianna Fontana; Ana Martinez-Naharro; Candida Cristina Quarta; Carol J Whelan; Aviva Petrie; Dorota M Rowczenio; Janet A Gilbertson; David F Hutt; Tamer Rezk; Svetla G Strehina; Joan Caringal-Galima; Richa Manwani; Faye A Sharpley; Ashutosh D Wechalekar; Helen J Lachmann; Shameem Mahmood; Sajitha Sachchithanantham; Edmund P S Drage; Harvey D Jenner; Rosie McDonald; Ottavia Bertolli; Alan Calleja; Philip N Hawkins; Julian D Gillmore Journal: Circulation Date: 2019-05-21 Impact factor: 29.690
Authors: Diane M Turner-Bowker; Roger E Lamoureux; Jonathan Stokes; Leighann Litcher-Kelly; Nina Galipeau; Andrew Yaworsky; Jeffrey Solomon; Alan L Shields Journal: Value Health Date: 2018-03-07 Impact factor: 5.725
Authors: Philip N Hawkins; Yukio Ando; Angela Dispenzeri; Alejandra Gonzalez-Duarte; David Adams; Ole B Suhr Journal: Ann Med Date: 2015-11-27 Impact factor: 4.709